Daily Roundup

HIQ.ASX FBR.ASX EBO.ASX IMR.ASX SPA.ASX

Strong Growth for HITIQ, FBR, EBOS, and Imricor

HITIQ Ltd has issued 1 million new shares at $0.03 each to settle $30,000 owed to an external investor relations provider. The shares were issued from the company's ASX Listing Rule 7.1 placement capacity.

Over at FBR Ltd, the company has appointed Mark Pivac as the new CEO, replacing Mike Pivac who is retiring. FBR's board will be reduced to 4 members, including 3 non-executive directors who have agreed to a reduced base salary of $50,000 per annum. The changes are part of FBR's cost rationalisation program as it continues to explore opportunities in industries like steel, mining, and energy.

EBOS Group Limited has successfully completed a fully underwritten $200 million placement, which will provide balance sheet capacity for future growth opportunities. The company also plans to conduct a non-underwritten retail offer of up to $50 million for eligible existing shareholders.

Imricor Medical Systems has reached an exciting milestone, performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Centre. This marks the initiation of Imricor's VISABL-VT clinical trial, signaling a new era for the company and electrophysiology procedures.

Spacetalk Delivers Strong Q3 Results

Spacetalk Ltd reported impressive Q3 FY25 results, with a 47% year-on-year increase in paid mobile subscribers to 42.5k and a 21% growth in Annual Recurring Revenue to $11.6 million. Revenue also grew 26% to $5.1 million, driven by hardware sales and mobile subscriber growth. Spacetalk is expanding internationally and developing new products to drive further growth in its recurring, scalable business model.